Related Experiment Video
Updated: Jun 9, 2026
12:18
A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
Management of mixed dementia
1Rehabilitation and Geriatrics Department, Geneva University, Thônex, Switzerland. dina.zekry@hcuge.ch
Drugs & Aging
|September 3, 2010
Summary
Diagnosing mixed dementia (MD) is challenging, but treatments like cholinesterase inhibitors show benefits for cognitive and functional outcomes. Addressing cardiovascular risk factors is also key for prevention strategies.
Area of Science:
- Neurology
- Geriatrics
- Pharmacology
Background:
- Alzheimer's disease (AD) and vascular dementia (VaD) are leading causes of dementia in the elderly.
- Distinguishing between isolated AD, VaD, and mixed dementia (MD) is a significant diagnostic challenge.
- MD is a common pathology in older adults, necessitating accurate diagnosis for epidemiological and therapeutic purposes.
Purpose of the Study:
- To review the diagnostic challenges and therapeutic strategies for mixed dementia (MD).
- To evaluate the efficacy of current treatments for MD.
- To highlight the importance of managing cardiovascular risk factors in MD prevention.
Main Methods:
- Review of existing pharmacological studies and clinical trials on dementia treatments.
- Analysis of post hoc trial data for AD and VaD subgroups.
- Examination of neuropathological findings regarding MD prevalence.
Main Results:
- Cholinesterase inhibitors demonstrate reproducible cognitive and functional benefits in MD patients, comparable to those in AD.
- Limited data exist for memantine in MD, with a need for further randomized controlled trials.
- Treatment of cardiovascular risk factors, particularly hypertension, may offer neuroprotective benefits.
Conclusions:
- Accurate diagnosis of MD is critical for effective patient management and research.
- Cholinesterase inhibitors are a viable treatment option for improving outcomes in MD.
- Integrated prevention strategies including cardiovascular risk factor management are essential for brain health in the elderly.
Related Concept Videos
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:30Cognitive Development During Adulthood
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...